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 Abstract  
Aims: Gene dosage can have a major impact on cell biology although, hitherto, is has been 
difficult to study using in-vitro models. We sought to refine and accelerate the development of 
“gene dosage” models through using CRISPR/Cas9 (a gene-editing technology) for sequential 
knockout of gene alleles.  
Methods: Our method involved (i) using Cas9 nuclease mRNA rather than expression plasmids, 
(ii) using a fluorescently labelled FAM-6 tracr complexed with guide RNA and (iii) using High 
Resolution Melting (HRM) analysis to screen for mutations. HCT116 cells, wild-type for TP53, 
were transfected with different molarities of FAM-6 tracr labelled and guide RNA targeting 
different exons of TP53 and selected by Fluorescence Associated Cell Sorting (FACS). Single-
cell colonies were then isolated, expanded and tested for mutation in the targeted region by 
PCR/HRM.   
Results: Out of 32 clones tested, 12 have shown aberrant melting by HRM, giving a targetting 
efficiency of 37.5%. One clone was sequenced and a heterozygous mutation found  - in this case 
comprising a single base deletion in exon 3. mRNA sequencing confirmed the mutation was 
expressed and western blotting for p53 showed the presence of both wild type and truncated 
protein bands. Changes in expression of MDM-2 isoforms suggested a functional effect of the 
induced TP53 mutation.  
Conclusions: We have developed an in-vitro model to study TP53 gene dosage effects. The 
protocol is efficient and applicable to any gene. Importantly, we have used Cas9 mRNA and 
labelled tracr/guideRNA to isolate likely-mutated cells and HRM for rapid mutation detection.  
  
 Introduction 
CRISPR (clustered, regularly interspaced, short palindromic repeat) and Cas (CRISPR-
associated) proteins are present in bacteria and archea species. In combination, they form a system 
which recognizes and cleaves foreign nucleic acid derived from phages and plasmids. This system  
functions as  an adaptive immune response to prevent an invading virus from inserting  its genome 
into the host bacterial genome[1]. In one of the most transformative technical developments in 
recent years, this system has been adapted to allow editing of mammalian genes. 
Although there are now many different strategies[2,3], the most commonly used system for 
gene editing is the CRISPR/Cas9 system. This depends on the helicase and endonuclease activity 
of wild-type Cas9 protein to create mutations at specific target sites by  cleaving  double stranded 
DNA. This is followed by one of two forms of repair (i) non-homologous end joining (NHEJ) 
repair – a error prone process which is characterized by frequent insertion or deletion of 
nucleotides resulting in frameshift mutations and early stop codons[4] or (ii) homology directed 
repair (HDR) in which an exogenous DNA template is used to induce misense mutations[5].  
Cas9 can be directed to cleave any gene of interest in eukaryotic cells by introducing a 
synthetic guide RNA (sgRNA) sequence. The sgRNA has two components including a CRISPR 
RNA (crRNA) which contains sequences complementary to (and thereby identifying) the target 
gene and adjacent short sequences called Proto-spacer Adjacent Motif (PAM)[6]. The second 
component is a sequence called trans-acting CRISPR RNA (tracr-RNA) which is essential for 
activating the Cas9 protein. By pooling different guide RNA/Cas9 complexes, a multiplex editing 
of target loci can be achieved[7]. The sgRNA and Cas9 can be packaged into a plasmid and gene 
editing can begin by transfecting the construct into cells. The successfully transfected cells need 
to be identified and this can be done with a fluorescently tagged Cas9 protein. These cells are then 
grown as single cell colonies and then they need to be tested for the induction of mutation. This is 
most commonly done using PCR followed by enzymatic cleavage of heteroduplexes which 
 naturally form when mutant and wild type gene sequences are co-amplified. Once a clone has been 
identified to contain the required mutation, its cells can then be used to target the other allele[8].  
One of the disadvantages of CRISPR/Cas9 gene editing is the possibility of inducing 
additional off-target genetic modifications i.e. mutation of a different gene. This could confound 
experimental work and would limit use of CRISPR/Cas9 for therapeutic purposes[9]. Off-target 
mutations could be reduced through limiting the time frame for the activity of Cas9 by transfecting 
Cas9 mRNA (or its ribonucleoprotein) into the target cells instead of  Cas9-expressing plasmid 
DNA. By electroporating Cas9 ribonucleoprotein directly, several groups have been able to 
efficiently induce RNA-guided engineered nucleases (RGENs) activity [10,11] and Kim and 
colleagues have sugessted that in principle, Cas9 protein can be replaced with Cas9 mRNA, which 
is easily transcribed but not integrated into the host genome[12]. Cas9-transcript could still be 
detected 96h post-transfection of Cas9-expressing plasmid DNA whereas it was absent for the 
same time point in the case of Cas9 mRNA transfections [13]. Liang and colleagues have also 
reported reduced rates of off-target mutations produced by using Cas9 mRNA and 
ribonucleoprotein versus Cas9-expressing plasmid DNA [14]. 
In this study, we sought to develop a protocol for gene dosage studies. We have employed 
Cas9 mRNA because (i) it is easier to transfect into the cells than plasmids, (ii) it is translated 
rapidly into Cas9 protein in the cytoplasm (thereby obviating the need for nucleofection) and (iii) 
it is rapidly degraded thereby reducing the duration of action of Cas9 and reducing the risks of 
both bi-allelic mutation and off-target gene editing. Additionally, a FAM-6 labelled tracr was 
complexed with guide-RNA and Cas9 mRNA to allow for flow-assisted cell sorting of sucessfully 
transfected cells. Finally, we used High Resolution Melting (HRM) to screen for mutations as it 
is quick and could be used for screening for mutations in both the first round and the second round 
of targetting. TP53 was chosen as a target gene to test the feasibility of Cas9 mRNA-based 
CRISPR as it is an important tumor suppressor gene[15].  
 Materials and Methods 
Cell culture 
HCT116, a colorectal cancer cell line previously shown to be wild type for TP53[16] was 
obtained from the American Tissue Culture Collection (ATCC). It was cultured in high glucose 
DMEM (Gibco, 41965-062) supplemented with 10% foetal bovine serum, 2mM L-glutamine 
(Sigma Aldrich) and maintained in a humidified incubator at 37°C in a 5% CO2 atmosphere. Cells 
were regularly passaged at 70-80% confluency and experiments performed up to passage number 
20. 
Transfection 
Lipofectamine® messengerMAX (Invitrogen, LMRNA001) was employed as a transfection 
reagent. During the transfection cells were maintained in Opti-MEM I Reduced Serum Medium 
(Gibco, 31985062).  
Wild type Cas9 mRNA, capped and polyA-tailed, at a concentration of 500ng/µL was 
purchased from Sigma Aldrich (St Louis, MO, USA). Guide RNAs including crRNAs designed 
to target the first 3 exons of TP53 (Figure 1) as well as the FAM6-labelled and unlabelled tracr 
RNA oligos were kindly supplied by Dr Gulpreet Balrey (Merck, UK).  
Cells were seeded in 24-well plates at a density of 1.2х 105 cells/ well and left to adhere 
overnight in a humidified incubator at 37ºC, 5% CO2. Transfection was initiated at 70% 
confluence. The growth medium was changed from DMEM to Opti-MEM Reduced Serum 
Medium 1hour before transfection. Transfection was performed using a mixture of 500ng per well 
of Cas9 mRNA, 8, 16 or 24pmol of 3 different guide crRNA (Table1) which were designed to 
target three different exons of TP53. Equimolar quantities of crRNAs and tracrs (unlabelled tracrs 
were used as a negative control) were complexed for 5 minutes in 25L of Opti-MEM. Separately, 
1.5L of Lipofectamine MessengerMAX was complexed with 25L Opti-MEM for 5min. The 
 diluted Cas9 mRNA, sgRNA (complexed crRNA and tracrRNA) were added to diluted 
lipofectamine messenger MAX, gently mixed and incubated for 10 min at room temperature, while 
protecting it from light. The mixture was added drop-wise to each well and each experiment was 
performed in triplicate. 
The cells were incubated in a humidified incubator at 37ºC, 5% CO2 and after 6 hours Opti-
MEM was replaced with complete DMEM, 10% FBS, 2mM L-glutamine and incubated for 72 
hours.  
Guide 
RNA 
Genomic 
coordinates 
ID: 
NG_017013.2 
Length 
(bp) 
GC(%) Target* Sequence 5’-3’ 
sgRNA1 18311 - 18329 41 48.7 Exon 3 CUGCAUGGGCGGCAUGAACGUUUUAGAGCUAUGCUGUUUUG 
sgRNA2 17440 -  17458 41 46.3 Exon 1 GCACAUGACGGAGGUUGUGGUUUUAGAGCUAUGCUGUUUUG 
sgRNA3 17589 - 17608 41 41.4 Exon2 UCGGAUAAGAUGCUGAGGAGUUUUAGAGCUAUGCUGUUUUG 
FAM6-
tracr 
 69 42.0 N/A [FAM6]AAACAGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAU
CAACUUGAAAAAGUGGCACCGAGUCGGUGCU 
Table 1 - Guide RNA sequences, respective genomic coordinates, target exonsreferring to transcript variants 5,6 and 7 of 
human TP53 and FAM-6 labelled tracr sequence. 
 
Flow cytometry and single cell colony formation 
At 72 hours post-transfection, cells were dissociated with 0.25% Trypsin-EDTA for 3-5 min 
at 37°C, resuspended in 10% FBS DMEM followed by three washes in PBS after a centrifugation 
step (1500rpm, 5 min). Fluorescence-activated cell sorting (FACS) was performed using a 
Beckman Coulter MoFlo XPD, on the FL1 channel, which was compatible with detection of the 
FAM-6 fluorophore (excitation at 496 nm, emission 516nm). Cells in which transfection was 
performed with sgRNA containing unlabelled tracr were used as a negative control of background 
fluorescence levels. The pools of cells transfected with 16pmol  sgRNA3, and 24 pmol sgRNA1 
and 2 were chosen for sorting, and were re-sorted to obtain a nearly 100% positive FAM-6 positive 
cell population. The final sorted cells were firstly grown to create a stock which was cryopreserved 
and also to collect conditioned media of each pool of sgRNA sorted cells, resuspended at a density 
 of approximately 10 cells/mL and 100uL was pipetted into each well of a 96-well plate. This 
equates to seeding 1 cell per well. Two 96-well plates for each sgRNA were seeded with 
approximately one cell per well to allow the isolation of single cell clones.  Each well was 
supplemented with 100 µL of conditioned media (48h) collected from the respective pool of sorted 
cells, to enhance the formation of single colonies. The single colonies that formed in a 96-well 
plate were then expanded successively into larger capacity plates (24-well plates, 6-well plates) 
and ultimately T25 flasks. At this point, each of the expanded clones was split for DNA extraction 
and cryopreservation in a solution of 10%DMSO, 90% fetal bovine serum.  
 
PCR for High-resolution melting analysis of single cell clones 
Genomic DNA was extracted from cell pellets of each clone using GenElute™ Mammalian 
Genomic DNA Miniprep Kit (Sigma Aldrich, G1N70) following the manufacturer 
recommendations. The eluted DNA was quantified using nanodrop 2000 (ThermoScientific) and 
diluted to 20ng/µL. 
Using primers flanking the regions targeted by the three sgRNAs (Figure 1). PCR was 
performed in triplicates for subsequent high-resolution melting analysis. Briefly, 40ng of genomic 
DNA template from each clone was added to a PCR mix containing 7.5 µL of 2x PCR master mix 
hotshot diamond (Clent Life Science, HS002), 1 µL  Eva Green dye and 250nM primer. The PCR 
reaction was performed in a final volume of 15µL on a PeqLab primus thermocycler set at 95°C 
for  5 min, followed by 40 cycles of 95°C for 20 sec, 60.5° for 20sec and 72°C for 20sec, followed 
by an extension step at 72°C for 5min, 95°C for 2min for heteroduplex formation and holding at 
4°C. The primer sequences used for the PCR are shown in Table 2 and their respective positions 
are illustrated on Figure 2. 
HRM was used to screen for mutations through detecting small mutation derived-shifts in 
the melting temperature of PCR products. HRM has been described as exceptionally sensitive 
 when there are heterozygous mutations as these result in the formation of heteroduplexes which 
are very unstable [17,18]. PCR products were melted in triplicates by firstly transferring 10µL to 
a 96-well black hardshell plate (Bio-Rad laboratories, HSP9661) and overlaying with 20µL 
mineral oil (Sigma Aldrich, M5904). After a short centrifugation for 5 min at 2500 rpm, the 
melting was performed on a lightscanner (Idaho technologies, Biofire Defense) pre-heated to 
62°C. The range of melting temperatures varied with product sizes and sequences analysed, but 
was set to detect melting peaks from 95-70°C. Exposure was set to ‘Auto’ and data were captured 
at a ramp rate of 0.10C/sec. The acquired melting data were analysed with the LightScanner Call-
IT software version 2.0.0.1.331. Results were viewed as ‘Shifted melt curves’ and ‘Difference 
curves’ outputs. The criteria for selecting mutant clones were the quality of template DNA, the 
reproducibility of the aberrant melting patterns on separate PCR runs and the consistency amongst 
the three replicates. 
 
Primer Sequence 5’-3’ Length (bp) GC(%) Tm (°C) 
E1F GCCATCTACAAGCAGTCACA 20 50.00 57.90 
I1R GCAATCAGTGAGGAATCAGAGG 22 50.00 58.80 
I1F CACTGATTGCTCTTAGGTCTG 21 47.62 56.08 
E2R CATAGGGCACCACCACACTA 20 55.00 59.09 
E3F TGGCTCTGACTGTACCACCA 20 55.00 60.47 
E3R GGAGTCTTCCAGTGTGATGATG 22 50.00 58.47 
I2Fseq CCTGCTTGCCACAGGTCT 18 61.11 59.57 
I3Rseq TGGAAGAAATCGGTAAGAGGTG 22 45.45 57.80 
I4Rseq* GTTGGGCAGTGCTCGCTTAG 20 60.00 61.64 
Table 2 - Primer sequences used for screening and sequencing. F indicates a forward primer and R a reverse primer. 
Primers marked seq were used for sequencing. *Spans junction between exons 4 and 5. 
 
RNA extraction, cDNA synthesis and RT-PCR 
RNA was extracted from mutant clones and wild-type HCT116 cell line using the total RNA 
kit (Sigma Adrich). DNAse I digestion was performed to eliminate contaminant genomic DNA. 
cDNA synthesis was carried out by using M-MLV transcriptase (Promega, M170A) and  2µg of 
RNA were combined with 0.5 μg of hexamer primers (ThermoFisher Scientific, SO142) and up 
 to12μl nuclease free water. The mixture was heated to 70°C for 5 minutes, immediately cooled to 
4°C and then the following were added: 5 μl of 5xM-MLV buffer, 1.75 μl of 10mM dNTPs 
(ThermoFisher Scientific, R0191), 25 units of RNAse inhibitor (Promega, N2111) and 200 units 
of M-MLV reverse transcriptase and nuclease free water to make a final volume of 25 μl. The mix 
was then incubated in a thermocycler for 60 min at 37°C, after which the cDNA was stored at -
20°C. 
RT-PCR was performed with 1µL of cDNA template, 1 unit of AmpliTaq 360 DNA 
polymerase (Applied Biosystems, 4398818), 1X AmpliTaq buffer, 400nM of primers (E1F/E4R 
and E3F/E3R), 200µM of dNTPs and 1.75mM of MgCl2. To prevent any secondary structure on 
the template that could have been caused by heteroduplex formation with the induced mutation, 
betain (Sigma Aldrich, B0300-1VL) at a final concentration of 1.3M and 1.3% DMSO PCR grade 
(Sigma Aldrich, D9170-1VL) were used in the RT-PCR. The cycling parameters were set at 94°C 
for 5 min, followed by 10 cycles of touchdown annealing temperature, decreasing 1°C/cycle (94°C 
– 15 seconds, 65 to 55°C – 30 seconds, 72°C – 40 seconds), 30 cycles of denaturation at 94°C for 
15seconds, annealing at 60°C for 30seconds and extension at 70°C for 40 seconds and a final 
extension at 72°C for 5 minutes with storage at 4°C. 
Cloning of PCR products 
In order to get the highest quality sequencing data, PCR products containing amplified 
cDNA from exons 1 to 4 was cloned into a pCR2.1-TOPO vector after purification using  
GenEluteTM PCR Clean-Up Kit (Sigma Aldrich, NA1020-1KT) according to the manufacturer’s 
instructions.  
For the ligation reaction, 46ng of purified PCR product were added to 10 ng pCR2.1-TOPO 
vector (Invitrogen, K450001), 1µL salt solution (1.2 M NaCl, 0.06 M MgCl2) and incubated for 
20 min at room temperature. Next, 2 μL of the ligation mix were added to a 50uL vial of One 
Shot® Chemically Competent E. coli (TOP10, Invitrogen, K450001), gently mixed, incubated on 
 ice  for 30min and then heat shocked for 30 seconds at 42°C then quickly returned to ice for 5 min. 
Next, S.O.C. medium (2% Tryptone, 0.5% Yeast Extract, 10 mM NaCl, 2.5 mM KCl, 10 mM 
MgCl2, 10 mM MgSO4, 20 mM glucose) was added and the mixture incubated for 1 hour at 37°C, 
shaking at 230rpm before spreading onto pre-warmed selective plates of Luria Broth (LB) agar 
containing 100ug/mL of ampicillin (Invivogen, fas-am-s), coated with 40uL of 40mg/mL X-gal 
in dimethylformamide. After overnight incubation at 37°C, 12 white colonies were picked, 
inoculated in 5mL of LB containing 100µg/mL ampicillin (Invivogen, fas-am-b), incubated for 
16h at 37°C and then used for plasmid DNA extraction following the instructions on the Genelute 
Plasmid Miniprep kit (Sigma Aldrich, PLN350). 
Sequencing and analysis 
The purified PCR products were diluted to 10ng/µL and cloned plasmids were diluted 
100ng/µL in nuclease free water. Sanger sequencing was performed at the DeepSeq facilities in 
the School of Life Sciences at the University of Nottingham using dye terminator chemistry 
(BigDye version 3.1) on the 3130xl ABI PRISM Genetic Analyzer . The obtained sequences were 
analysed with BioEdit software version 7.2.5 and aligned to human genomic or transcript TP53 
sequences using Mega software version 7.0.1.8. Translation of gene sequences of wild-type TP53 
isoform A (NCBI RefSeq: NG_017013.2, Homo sapiens tumor protein p53 (TP53), RefSeqGene 
(LRG_321) on chromosome 17) and mutant clone G11A8 with a point deletion, was performed 
using the online translation tool Expasy (http://web.expasy.org/translate/) and the respective 
protein alignments were performed on Mega software version 7.0.1.8. 
Western Blot 
Wild-type and clone G11A8 HCT116 cells seeded at a density of 106 cells/well were 
incubated overnight and then lysed using ice-cold RIPA buffer (ThermoFisher Scientific, 
10017003) , incubated for 10minutes on ice with 1x Halt protease and phosphatase inhibitor 
(ThermoFisher Scientific, 78440)  and then centrifuged for 30minutes at 16,000xg and 4°C. The 
 supernatant was collected and quantified by BCA assay (ThermoFisher Scientific, 23225). Thirty 
µg of protein were mixed with 4x LDS sample buffer (Invitrogen, 11549166), loaded into a 4-
12% Bis-Tris Nupage Gel (Invitrogen, NP0321BOX) and run at constant voltage of 150V for 90 
min. Protein was transferred onto a nitrocellulose membrane using a semi-dry transfer system 
(Bio-rad laboratories, Turbo-blot) which was incubated in blocking buffer (5% skimmed milk in 
TBST (Tris buffer saline, pH 7.6, 0.1% Tween 20)) for 1hour and then hybridised overnight at 
4°C with mouse monoclonal TP53 antibody at 1:200 dilution (DAKO, clone do-7, M700101-2) 
and MDM2 at 1:500 dilution (Abcam, ab3110), diluted in blocking buffer. Mouse anti-human 
beta-actin (1:2000 dilution in blocking buffer, Sigma Aldrich, A5441) was used as a loading 
control and the membrane was incubated for 2 hours at room temperature. After 3x washes of 
5min each in TBST, the membranes were incubated for 1 hour at room temperature with secondary 
HRP-conjugated Rabbit anti-mouse IgG (Sigma Aldrich, A6154), diluted 1:1000. After another 
3x5min washes with TBST and incubation with ECL prime (GE Healthcare, RPN2236) for 5min, 
the membranes were scanned with a digital scanner (Li-cor, C-digit) to detect chemiluminescence. 
Results 
Identification of targeted cell pools 
By using flow cytometry to detect FAM-6 labelled tracr transfected in the cells, we were 
able to detect and identify the molarities showing best FAM-6 labelling in the population of cells 
succesfully transfected with sgRNAcontaining FAM6-labelled tracr and Cas9 mRNA (Figure 3). 
The labelled population ranged from 1.67 to 4.55% in the pooled triplicates containing over 3x106 
cells. The sorted cells were enriched in a second sorting, increasing FAM-6 positivity purity from 
the initial 50-80% obtained in the first sorting (Figure 4). 
  
Isolation of single cell clones 
In total, 32 colonies were selected for further expansion, genomic DNA extraction and 
cryopreservation. The 3 pools of selected sgRNA1, sgRNA2 and sgRNA3 initially targeted cells 
were also cryopreserved to allow a repeated selection of single cell clones in case a mutant clone 
could not be detected. . 
 
Detection of mutant clones by high-resolution melting (HRM)  
HRM was used to screen for the presence of mutant clones isolated from the pools of sg 
RNA1,2 and 3 targeted cells. The use of normal template genomic DNA from untargeted HCT116 
in the PCR reactions served as a baseline control to which shifts in melting temperatures could be 
compared. Of the 32 clones which were tested, 12 (37.5%) showed aberrant metling (Figure 5). 
 
Confirmation of indel mutation and its expression by sequencing 
HRM is a robust method for mutation detection and one clone, G11A8, was selected for 
further expansion and testing. In order to confirm that mutation, mRNA was extracted, reverse 
transcribed and the coding sequence spanning exons 1- 4 of TP53 was cloned and sequenced. 
Analysis of the sequencing data showed that the selected clone contained both wild type and 
mutant sequence thereby confirming the heterozygous nature of the mutation (Figure 6).  The 
mutation consisted of a single G deletion within the region complementary to the targeting 
sequence of sgRNA1 - CTGCATGGGCGGCATGAAC (deleted base underlined). This 
corresponds to the mutation c735delG in the TP53 coding sequence. Usually frameshift mutations 
(insertions or deletions which are not a multiple of three) result in a truncated protein. The new 
 sequence created as a consequence of the c735delG mutation, when translated, is predicted to 
produce a truncated protein of 343 amino acids with a molecular weight of 41kDa (Fig 7C). 
 
Confirmation of truncated TP53 protein and its functional effect  
Having confirmed that the mutation was present at the mRNA level, we sought to confirm 
that the mutation led to a truncated protein form. A western blot with protein lysates from both the 
parental cell line HCT116 (wild-type for TP53) and mutated clone G11A8 was performed. The 
parental cell line contained a single band of correct size (approximately 53kDa). The mutated 
clone showed both the wild type band and an extra band, corresponding to the predicted truncated 
TP53 protein of approximately 41kDa (Figure 7A). To confirm that there was a functional 
consequence of the induced mutation, we performed a Western blot for MDM2. This protein has 
a complex relationship with p53 as it is both a target of p53 and an inhibitor of p53. Comparison 
of the parental HCT116 with the mutated clone G11A8 confirmed that there was indeed a 
functional effect with a change in the pattern of MDM2 splice variants in the mutated clone (Figure 
7). When aligning the translated wild-type coding sequence of human TP53 isoform A 
[(NG_017013.2:15957-16030, NG_017013.2:16148-16169, NG_017013.2:16279-16557, 
NG_017013.2:17315-17498, NG_017013.2:17580-17692, NG_017013.2:18261-18370, 
NG_017013.2:18714-18850, NG_017013.2:18943-19016, NG_017013.2:21836-21942, 
NG_017013.2:22861-22942) Homo sapiens tumor protein p53 (TP53), RefSeqGene (LRG_321) 
on chromosome 17] with the respective G11A8 presenting point deletion on the gRNA1 target site 
(CTGCATGGGCGGCAT[G]AAC), a significant change in the protein can be observed from the 
point mutation occurring. When a guanine (G) is deleted in the ATG codon, which would translate 
into methionine in the wild-type protein, a frameshift occurs to synthesize isoleucine (a.a. 246) 
(Figure 7B) and missense amino acids follow, until a stop codon is produced. 
 Discussion 
In cancer biology, changes in gene dosage may have a significant effect on cell biology. 
Oncogenes such as -catenin depend on “just right” signalling for maximum activity[19], tumour 
suppressors, such as TP53, would be expected to confer some selective advantage following 
somatic mutation (prior to loss of heterozygosity) and some tumor suppressors, such as PARK2, 
appear to mediate effect through haploinsufficiency[20]. We have sought to develop an efficient 
protocol to establish models for gene dosage studies by taking advantage of recent technical 
developments in gene editing and combining these with FACS and HRM to enrich for the target 
population and screen for mutations. Using this methodology, we have induced a heterozygous 
truncating mutation in TP53 and shown that it causes a change in the pattern of MDM2 expression.   
The first step in our method involved introduction of the sgRNA and the Cas9 mRNA into 
the cells through lipid-based transfection. This would result in a pulse of gene editing activity 
(lasting until the mRNA was degraded) rather than the constant editing activity which may be 
expected if inducing CRISPR/Cas9 machinery from a DNA plasmid expression vector. Therefore, 
the  main advantage of this methodology is a reduction of  off-targets gene editing as  the translated 
Cas9 protein has a short half-life and reduced editing time[14].  
After single cell cloning, the next step was to screen the clones for the presence of somatic 
TP53 mutation. Rather than performing genomic cleavage detection (GCD) on targeted cells, we 
used HRM with strigent criteria to identify the presence of single mutant clones in our 
methodology. HRM has a number of advantages over GCD. HRM is a cheap, simple  and very 
sensitive method for mutation screening, performed in a closed tube, immediately after PCR[21]. 
In contrast, GCD requires PCR products to undergo a enzymatic digestion followed by resolution 
on an agarose gel in order to identify cleaved PCR products. Another advantage of HRM is that 
each heteroduplex has a unique melting pattern and thus, if there is a second round of 
CRISPR/Cas9 editing to produce a homozygous mutant, HRM can be used to distinguish colonies 
 with double mutations from single mutations. In contrast, GCD could not do this since the 
mismatches leading to heteroduplex formation will be approximately in the same position whether 
single or double mutations and this will lead to cleavage fragments of the same size, 
Aberrant melting patterns were observed for 37.5% of the clones. Depending on the cell line 
and transfection method, this is commensurate with the range of efficiencies found by Liang et al 
targeting HPRT using the Cas9 mRNA format in several established and primary human cell lines 
(0-70%), even though efficiency of gene editing in HCT116 cell line was not tested[14]. However, 
in the study by Liang et al, the induced mutations were not tested in individual single cell colonies 
but were inferred from PCR product cleaved fragment density from PCR performed on pooled 
colonies, therefore our results are not in comparable terms.  
In summary, we have combined several methods to develop a CRISPR/Cas9 -based system 
for creating models for studying gene dosage effects. The methodology was used to create a 
heterozygous truncating mutation of TP53 which resulted in changes in MDM2 expression. Our 
protocol is rapid, it will probably reduce off-target effects, FACS enrichment allows isolation of 
a single cell clone with a high probability of mutation and HRM allows mutation detection in both 
the heterozygous and the homozygous state.  
Key messages 
 A gene dosage model was developed by applying a variant of the CRISPR/Cas9 
method involving the use of Cas9 mRNA and FAM6 labelled sgRNA. 
 High-Resolution Melting (HRM) was applied to screen for mutant clones instead of 
enzymatic Genomic Cleavage Detection. 
 A TP53 heterozygous truncating mutation was created, resulting in changes in 
MDM2 expression. 
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